Wacker Biotech is “The Microbial CMO” — the partner of choice for process development and contract manufacturing of biopharmaceuticals (proteins, vaccines, and live microbial products) using microbial hosts. WACKER’s integrated service portfolio covers molecular biology, process/analytical development, and good manufacturing practice (GMP) manufacturing of biologics for clinical and commercial supply.
WACKER operates three state-of-the-art GMP facilities located in Europe (Germany and The Netherlands). Manufacturing lines with two 300-L and two 1,500-L stainless steel fermentation vessels, single-use fermentation lines, matching downstream processing scales and fill and finish capabilities are available to suit all possible customers’ needs (BSL 1 and 2).
WACKER holds biomanufacturing certificates from the relevant authorities for all sites and follows the ICH Q7A guidelines for GMP-compliant production of active pharmaceutical ingredients (APIs) and drug products (DPs). All three GMP production facilities are approved for commercial manufacturing by EMA, US FDA, and/or ANVISA.
WACKER rounds out its offerings with outstanding Escherichia coli technologies that can increase bioprocess efficiency significantly and thus reduce cost of goods.
Just fill out the form below to read the full capabilities review now.